Currently, the follow-up for prostate cancer patients includes the use of serological tests [20], such as the blood evaluation of Prostate Specific Antigen (PSA) [20], or imaging analysis by Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) [21] or 18 F-choline PET/Computer Tomography [22]. This evidence concerns the gene KLK3 and prostate cancer.